Differences in Quality of Life between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients with Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

John M. Burke, Richard H.C. Van Der Jagt, Brad S. Kahl, Peter Wood, Tim E. Hawkins, David Macdonald, Mark Hertzberg, David Simpson, Michael Craig, Kathryn Kolibaba, Samar Issa, Mihaela Munteanu, Timothy W. Victor, Ian W. Flinn

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Background We previously reported results of the phase III, randomized, noninferiority trial comparing bendamustine-rituximab (BR) with standard R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone)/R-CVP (rituximab/cyclophosphamide/vincristine/prednisone) in previously untreated advanced indolent non-Hodgkin and mantle cell lymphomas. Here we report health-related quality of life (HRQOL) results from the trial. Methods HRQOL, as measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), was a secondary end point. Differences between group means in global health status (GHS), 5-item functioning, and 9 symptoms/single-item measures at week 1 of cycle 1 and end-of- cycles 3 and 6 were examined using the screening (baseline) score as a covariate in analysis of covariance. Results Overall EORTC QLQ-C30 compliance was 75.2%, 89.5%, and 89.9% at week 1 of cycle 1 and end-of-cycles 3 and 6, respectively. Patients treated with BR reported improvements in Cognitive Functioning, Physical Functioning, Social Functioning, Emotional Functioning, and GHS as well as reduction in dyspnea, constipation, and fatigue at some, but not all, time points. Patients treated with standard therapy reported less nausea/vomiting at one time point. Conclusion Compared with patients treated with standard therapy, patients treated with BR reported better quality of life in several areas.

Original languageEnglish
Pages (from-to)182-190.e1
JournalClinical Lymphoma, Myeloma and Leukemia
Volume16
Issue number4
DOIs
StatePublished - Apr 1 2016

Keywords

  • BRIGHT trial
  • EORTC QLQ-C30
  • First-line therapy
  • Patient-reported outcomes
  • Phase 3

Fingerprint

Dive into the research topics of 'Differences in Quality of Life between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients with Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma'. Together they form a unique fingerprint.

Cite this